Improving the lives of people suffering from mental illness and substance use disorders

What we do

Pharmaceuticals

Pharmaceuticals

Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

MODIA™ - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

Key News

NOVEMBER 26, 2021
Orexo provides information about its new proprietary drug delivery platform – amorphOX™

NOVEMBER 16, 2021
Positive results from pivotal trial for OX124

NOVEMBER 3, 2021
Q3 Interim Report - Steady progression on our journey to build a broader and stronger Orexo

Orexo Social

29 November 2021

Today #orexo looks forward to present at @aktiespararna Stora Aktiedagen. At 2 pm Nikolaj Sørensen CEO will give a… https://t.co/k9oRXZLJUe

26 November 2021

amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different… https://t.co/uuH4sJEwfT

26 November 2021

Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will… https://t.co/V0s2CTLGcQ

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

News Flow

Regulatory Press Releases

Financial Snapshot

Group net revenues

580 MSEK

LTM1

Group EBITDA

-112 MSEK

LTM1

US Pharma segment EBIT

301 MSEK

LTM1

Cash position

588 MSEK

Q3 2021

1 Last Twelve Months, Q420-Q321, for more information about financial development Link